← 返回

髓母细胞瘤的细胞免疫治疗

英文原题:Cellular immunotherapy for medulloblastoma.

查看英文原题

Cellular immunotherapy for medulloblastoma.

PubMed 2023/04/06(内容时间) Neuro Oncol Q1 · IF 13.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

髓母细胞瘤(MB)是儿童中最常见的恶性脑肿瘤,约占所有儿童原发性脑肿瘤的20%。目前的治疗包括最大程度的手术切除以及积极的放疗和化疗。三分之一的接受治疗的患者无法治愈,而幸存者往往留下毁灭性的长期副作用。这一患者群体迫切需要新的高效靶向治疗。细胞免疫治疗旨在增强和利用免疫细胞靶向肿瘤,并已在多种癌症中被证明是成功的。然而,对于MB,细胞免疫治疗的知识和可能性仍然有限。在这篇综述中,我们全面概述了MB细胞免疫治疗的现状,从基础体外研究到体内模型以及(正在进行的)临床试验。此外,我们将我们的发现与胶质瘤——一种类似MB的颅内肿瘤——的细胞免疫治疗进行了比较。最后,讨论了MB未来的可能性,以提高疗效和安全性。

展开英文摘要原文

Medulloblastoma (MB) is the most common malignant brain tumor in children, making up ~20% of all primary pediatric brain tumors. Current therapies consist of maximal surgical resection and aggressive radio- and chemotherapy.

A third of the treated patients cannot be cured and survivors are often left with devastating long-term side effects. Novel efficient and targeted treatment is desperately needed for this patient population. Cellular immunotherapy aims to enhance and utilize immune cells to target tumors, and has been proven successful in various cancers.

However, for MB, the knowledge and possibilities of cellular immunotherapy are limited. In this review, we provide a comprehensive overview of the current status of cellular immunotherapy for MB, from fundamental in vitro research to in vivo models and (ongoing) clinical trials.

In addition, we compare our findings to cellular immunotherapy in glioma, an MB-like intracranial tumor.

Finally, future possibilities for MB are discussed to improve efficacy and safety.

论文信息

作者
Schakelaar MY、Monnikhof M、Crnko S、Pijnappel EW、Meeldijk J、Ten Broeke T、Bovenschen N
单位
Department of Pathology, University Medical Center Utrecht, 3584 CX Utrecht, The Netherlands.Netherlands
文献类型
综述 · 非美国政府资助研究
期刊
Neuro-oncology2023 Apr 6
原文标识
PubMed 36219688 · DOI 10.1093/neuonc/noac236